The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019
Infectious Diseases and Immunity
; 1(1):52-58, 2021.
Article
in English
| Scopus | ID: covidwho-2212932
ABSTRACT
Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and SARS-CoV-2 infection (causing coronavirus disease 2019 [COVID-19]) are serious diseases. To date, no effective post-exposure prophylaxis, prevention, or therapeutic agents are recommended as effective for these diseases. Convalescent plasma (CP), donated by individuals with established humoral immunity to the virus after recovering from coronavirus infection, has been successfully applied to treat several infectious diseases, including SARS, MERS, and COVID-19. Nonetheless, there are obstacles and challenges to using CP that should be taken into account. In this review, we summarize the evidence derived from clinical attempts to treat COVID-19 with CP, which represents a promising therapy for severe coronavirus infection. Furthermore, we outline the remaining challenges and general issues that should be considered when using CP treatment for therapeutic or prophylactic purposes. © 2021 The Chinese Medical Association, Published by Wolters Kluwer Health, Inc.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
Infectious Diseases and Immunity
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS